Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Limbal Stem Cell Deficiency Market Set to Transform During the Forecast Period (2025–2034) With Innovative Treatment Advances | DelveInsight

globenewswire.com
KALA Kala Pharmaceuticals is mentioned as a key company in the context of Persistent Corneal Epithelial Defects (PCED) and Limbal Stem Cell Deficiency (LSCD) pipeline analysis, indicating potential involvement but without specific sentiment. NOVM OOMA Oyster Point Pharma is mentioned as a key company in both the Persistent Corneal Epithelial Defects (PCED) market and Neurotrophic Keratopathy market, suggesting relevance to ocular surface disorders without specific sentiment. RGEN RegeneRx Biopharmaceuticals, Inc. is listed as a key company in the Neurotrophic Keratopathy market, indicating potential involvement in related therapeutic areas without explicit sentiment.

New York, USA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Limbal Stem Cell Deficiency Market Set to Transform During the Forecast Period (2025–2034) With Innovative Treatment Advances | DelveInsight

The dynamics of the limbal stem cell deficiency drugs market are anticipated to change owing to improvements in research and development, rising prevalence, and an aging population. Additionally, the expected launch of emerging therapies, such as Claris Biotherapeutics’ CSB-001, will further propel market growth.

DelveInsight’s Limbal Stem Cell Deficiency Market Insights report includes a comprehensive understanding of current treatment practices, emerging limbal stem cell deficiency drugs, market share of individual therapies, and current and forecasted limbal stem cell deficiency market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).

Limbal Stem Cell Deficiency Market Summary

Discover which limbal stem cell deficiency medications are expected to grab the market share @ https://www.delveinsight.com/sample-request/limbal-stem-cells-deficiency-lsd-market?utm_source=globenewswire&utm_medium=pressrelease&utm_campaign=spr

Sadaf Javed, Manager of Forecasting and Analytics at DelveInsight, commented: “The increasing prevalence of limbal stem cell deficiency, coupled with improving disease awareness, is driving greater demand for timely diagnosis and therapeutic intervention. This trend is expected to expand the addressable patient population and unlock incremental market opportunities. In parallel, ongoing research into topical therapeutic approaches for LSCD represents a significant advancement, with the potential to offer less invasive alternatives to surgical interventions such as limbal stem cell transplantation, thereby reshaping the treatment landscape.”

Key Factors Driving the Growth of the Limbal Stem Cell Deficiency Market

Limbal Stem Cell Deficiency Market Analysis

Learn more about the approved therapies for LSCD @ Limbal Stem Cell Deficiency Treatment Market

Limbal Stem Cell Deficiency Competitive Landscape

Claris Biotherapeutics is at the forefront of advancing CSB-001, a novel therapeutic candidate poised to transform the treatment paradigm for LSCD. With few competing assets in development, CSB-001 represents a compelling opportunity for industry stakeholders, offering renewed optimism for patients and the potential to redefine future LSCD management.

CSB-001 is a recombinant human dHGF-based ophthalmic formulation being developed by Claris Biotherapeutics for LSCD. Designed as a topical therapy, it is administered using a sterile droptainer, with a recommended dosing schedule of one drop four times daily. The product is stable at room temperature, supporting a patient-friendly and practical treatment approach.

Mechanistically, CSB-001 compensates for deficient hepatocyte growth factor (HGF) by engaging the c-MET receptor, a key mediator of corneal repair and regeneration. This differentiated mode of action has shown superior effectiveness in enhancing epithelial healing across corneal disorders. With its innovative biology and convenient delivery, CSB-001 holds strong potential to reshape LSCD treatment while creating meaningful value for both patients and market participants.

Aparna Thakur, Assistant Project Manager, Forecasting and Analytics at DelveInsight, commented: “The anticipated approval of novel therapies is expected to expand the treatment landscape and improve clinical outcomes. In particular, mesenchymal stromal stem cells (MSCs) and stem cells derived from allogeneic or autologous non-limbal sources have demonstrated encouraging potential and continue to represent key areas of focus within ongoing clinical research.”

To know more about pipeline therapies for LSCD, visit @ Limbal Stem Cell Deficiency Medication

What is Limbal Stem Cell Deficiency?

Limbal stem cell deficiency (LSCD) is a rare but vision-threatening ocular surface disorder caused by the loss or dysfunction of limbal stem cells, which are essential for the continuous regeneration of the corneal epithelium. When these cells are depleted, due to chemical or thermal burns, autoimmune diseases, long-term contact lens use, infections, or genetic conditions, the cornea loses its ability to maintain a clear, stable surface. This results in conjunctival overgrowth onto the cornea, chronic inflammation, recurrent epithelial defects, pain, photophobia, and progressive visual impairment. Early diagnosis is critical, as untreated LSCD can lead to irreversible corneal scarring and blindness, while advances in regenerative therapies and limbal stem cell transplantation are transforming long-term outcomes for affected patients.

Limbal Stem Cell Deficiency Epidemiology Segmentation

The limbal stem cell deficiency epidemiology section provides insights into the historical and current limbal stem cell deficiency patient pool and forecasted trends for the leading markets. Among the 7MM, the majority of LSCD cases diagnosed in 2024 were mild, followed by moderate and severe cases, with this trend anticipated to continue during the forecast period (2025-2034).

The limbal stem cell deficiency market report proffers epidemiological analysis for the study period 2020–2034 in the leading markets, segmented into:

Download the report to understand LSCD patient prevalence data by region with forecast @ LSCD Prevalence and Epidemiology Forecast

Scope of the Limbal Stem Cell Deficiency Market Report

Discover more about limbal stem cell deficiency drugs in development @ Limbal Stem Cell Deficiency Clinical Trials

Table of Contents

Related Reports

Limbal Stem Cell Deficiency Epidemiology

Limbal Stem Cell Deficiency Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted LSCD epidemiology in the 7MM, i.e., the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

Limbal Stem Cell Deficiency Clinical Trial Analysis

Limbal Stem Cell Deficiency Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key LSCD companies, including RHEACELL, Kala Pharmaceuticals, Surrozen, among others.

Persistent Corneal Epithelial Defects Market

Persistent Corneal Epithelial Defects Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key PCED companies including Eyevance, Amber Ophthalmics, Kala Pharmaceuticals, Noveome Biotherapeutics, Oyster Point Pharma, among others.

Persistent Corneal Epithelial Defects Clinical Trial Analysis

Persistent Corneal Epithelial Defects Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PCED companies, including Eyevance, Amber Ophthalmics, Kala Pharmaceuticals, Noveome Biotherapeutics, Oyster Point Pharma, among others.

Neurotrophic Keratopathy Market

Neurotrophic Keratopathy Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key neurotrophic keratopathy companies, including ReGenTree, RegeneRx Biopharmaceuticals, Inc., Oyster Point Pharma, Recordati Rare Diseases, MimeTech, Claris Biotherapeutics, BRIM Biotechnology Inc., among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.